lab technician or doctor handles a test tube
Representational Image | Commons
Text Size:

Munich: Swiss drugmaker Roche Holding AG said it’s introducing the first commercial test for the Wuhan coronavirus, which could help accelerate efforts to monitor the spread of the disease.

The pharmaceutical company said it’s ramping up production of high-tech machinery needed to use the tool. That could help resolve a thorny problem with the fast-spreading virus: so many people are getting sick in China that the laboratories that can screen for the virus are getting overwhelmed. That can cause delays, leaving hospitals unsure of who to quarantine and who can be sent home.

“There is a bottleneck,” Thomas Schinecker, head of Roche’s diagnostics division, said in an interview at the company’s Basel headquarters Thursday. “It’s really unknown how many people have the virus at the moment, and with our systems we can help to make testing much broader.”

The death toll from the virus has risen to 170 and more than 8,000 cases have been reported. The World Health Organization is meeting Thursday to consider declaring the virus an international public health emergency.

Roche, better known for developing cutting-edge drugs, doesn’t think any if its existing medicines would help coronavirus patients and isn’t looking to come up with a vaccine for the disease, Bill Anderson, head of Roche’s pharma unit, said in a separate interview.


Also read: What we know of coronavirus so far, and how Modi govt is monitoring it in India


Emergency Team

Roche’s emergency response team of molecular diagnosticians in San Francisco sprang into action a few weeks ago when word of the Wuhan virus emerged. Working with partners including Tib-Molbiol in Berlin, they created a test that can diagnose the disease within a couple of hours in a sufficiently staffed lab.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.

SUBSCRIBE NOW

The test analyzes nucleic acids extracted from patients’ saliva or mucus, and compares them against sequences found in coronavirus strains, including SARS and the one that emerged in Wuhan.

Demand is high for the test. Roche informed Chinese officials last week that it’s available and learned the country needs at least 150 instruments, Schinecker said. Other countries are ordering them, too, anticipating a surge of coronavirus patients within their own borders. The machines in demand — including Roche’s MagNA Pure 24 and the LightCycler 480 devices — are manufactured at its plant in Rotkreuz, Switzerland.

Hurdles have emerged. China’s decision to cordon off whole cities — while helping to curb the spread of the disease — is making it harder to deliver Roche’s equipment to hospitals located in hot spots, Roche Chief Executive Officer Severin Schwan told reporters Thursday. Roche is working with Chinese authorities to get shipments through as quickly as possible, Schwan said.

Meanwhile, Roche’s staff of 3,000 diagnostics unit workers in China are taking precautions against the pandemic, such as working from home as much as possible. That’s not possible for technicians needed to install, service and repair Roche’s machines. “This is life-critical, so we supply protection to our employees so that they can go in and do this work,” Schinecker said.

More Tests

Because Roche’s test hasn’t cleared any regulatory hurdles, hospitals that use its tool for the time being will need to validate the results with other tests, Schinecker said. That’s pretty standard for any pandemic. Regardless, Roche is trying to collect enough data to ensure that the test is working properly, while also scaling up its ability to screen patients thanks to larger machinery and automation. The emergency response team at Roche’s molecular diagnostics unit is keeping track of any changes to the coronavirus’s makeup so that its test stays valid.

If past outbreaks are any indicator, the surge in demand for Roche’s machinery won’t add too much to the company’s overall sales, which reached 61.5 billion francs ($63.4 billion) in 2019.

“In the big context, in terms of sales, it’s not super high,” Schinecker said. “But the impact you have on the health-care system is very important.”- Bloomberg


Also read: Alarmed over coronavirus, India to make list of viruses, bacteria to develop vaccines


 

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

Share Your Views

LEAVE A REPLY

Please enter your comment!
Please enter your name here